Black Cohosh Effective for Menopause

by | May 19, 2008

Researchers at Columbia University and George Washington University
have found a safe and effective alternative to synthetic drugs. Researchers examined the results of 29 independent studies on alternative treatments for hot flashes and found excellent support for the effectiveness of the herb Black cohosh.Women are rightly fearful of synthetic hormone replacement therapy (HRT) since Government scientists at the National Institutes of Health abruptly halted the nation’s biggest study on HRT in July 2002, saying long-term use of synthetic estrogen and progestin drugs increase a women’s risk of breast cancer by 26%, her risk of a heart attack by 29%, and her risk of stroke by 41% (SOURCE: JAMA. 2002;288:321-333).

Black cohoshBlack cohosh

Black cohosh, a member of the buttercup family, is among the most popular of alternative treatments for menopause. Most clinical studies involved a concentrated brand called Remifemin, manufactured and sold as a natural prescription drug in
Germany since the mid 1900’s, first by Schaper and Brummer (GmbH) and more recently by GlaxoSmithKline. Black cohosh has been used safely and effectively in Germany for almost 50 years with no evidence of any serious side effects, contraindications, or drug interactions.

Benefits
Benefits


In several clinical trials, Black cohosh has been shown to provide significant improvement in 86% of all patients within 4 weeks of onset of therapy. Studies show that Black cohosh reduces menopausal symptoms of hot flashes, perspiration, headache, vertigo, heart palpitations, ringing in the ears, nervousness, irritability, sleep disturbances, weariness, and depressive moodiness, while increasing motivation and emotional stability. A recent study also suggests that black cohosh may protect animals from osteoporosis (Phytomed 1996/7;3:379-85). Human studies have not confirmed this action.


How much is needed?
The recommended amount is 20-40 mg twice per day. The best-researched extract provides 1 mg of deoxyactein per 20 mg of extract.

Side effects
Very large amounts (over several thousand milligrams daily) of this herb may cause abdominal pain, nausea, headaches, and dizziness. In large scale clinical trials, none of the patients in clinical trials receiving Remifemin discontinued taking the supplement due to side effects. There are no known drug interactions with Black cohosh. Black cohosh is considered to be similar to Estriol, the healthy, protective estrogen, because it acts as a weak or partial antagonist to Estradiol (which is associated with increased risk of breast, ovarian, and endometrial cancer). Black cohosh is not recommended for pregnant or breast-feeding women due to lack of clinical studies on these women.

For more information about ESPROGEN, Dr. Hansen’s herbal female hormone balancing formula with Black cohosh, please click here.

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

15 + 5 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });